[1] Arendrup MC.Epidemiology of invasive candidiasis[J].Curr Opin Crit Care,2010,16(5):445-452.
[2] Cleveland AA,Harrison LH,Farley MM,et al.Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas,2008-2013:results from population-based surveillance[J].PLoS One,2015,10(3):e0120452.
[3] McCarty TP,Pappas PG.Invasive candidiasis[J].Infect Dis Clin North Am,2016,30(1):103-124.
[4] Mayer FL,Wilson D,Hube B.Candida albicans pathogenicity mechanisms[J].Virulence,2013,4(2):119-128.
[5] Mitchell AP.Microbiology:Fungus produces a toxic surprise[J].Nature,2016,532(7597):41-42.
[6] Flemming HC,Wingender J.The biofilm matrix[J].Nat Rev Microbiol,2010,8(9):623-633.
[7] Ostroskyzeichner L,Casadevall A,Galgiani JN,et al.An insight into the antifungal pipeline:selected new molecules and beyond[J].Nat Rev Drug Discov,2010,9(9):719-727.
[8] Cowen LE,Steinbach WJ.Stress,drugs,and evolution:the role of cellular signaling in fungal drug resistance[J].Eukaryot.Cell,2008,7(5):747-764.
[9] Shapiro RS,Robbins N,Cowen LE.Regulatory circuitry governing fungal development,drug resistance and disease[J].Microbiol Mol Biol Rev,2011,75(2):213-267.
[10] Denning DW.Echinocandin antifungal drugs[J].Lancet,2003,362(9390):1142-1151.
[11] Chandra J,Mukherjee PK,Hoyer LL,et al.Biofilm formation by the fungal pathogen Candida albicans:development architecture and drug resistance[J].J Bacteriol,2001,183(18):5385-5394.
[12] Kathwate1 GH,Karuppayi SM.Tramadol,an Opioid receptor agonist:an inhibitor of growth,morphogenesis,and biofilm formation in the human pathogen,Candida albicans[J].Assay Drug Dev Technol,2016,14(10):567-572.
[13] Zhu Z,Wang H,Shang Q,et al.Time course analysis of Candida albicans metabolites during biofilm development[J].Proteome Res,2013,12(6):2375-2385.
[14] Liao ZB,ZhangGuan XZ,Zhu ZY,et al.Enhancement of the antibiofilm activity of amphotericin B by polyamine biosynthesis inhibitors[J].Int J Antimicrob Agents,2015,46(1):45-52.
[15] Cao Y,Huang S,Dai B,et al.Candida albicans cells lacking CaMCA1-encoded metacaspase show resistance to oxidative stress-induced death and change in energy metabolism[J].Fungal Genet Biol,2009,46(2):183-189.
[16] Peleg AY,Jara SD.Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics[J].Antimicrob Agents Chemother,2009,53(6):2605-2609.
[17] Gu WR,Guo DM,Zhang LP,et al.Synergistic effect of azoles and fluoxetine against resistant Candida albicans attributed to attenuating fungal virulence[J].Antimicrob Agents Chemother,2016,60(10):6179-6188.
[18] Jia W,Zhang HY,Li CY,et al.The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms[J].BMC Microbiol,2016,16(1):1-10.
[19] Vuddanda PR,Chakraborty S,Singh S.Berberine:a potential phytochemical with multispectrum therapeutic activities[J].Expert Opin Investig Drugs,2010,19(10):1297-1307.
[20] Li D,Xu Y,Zhang DZ,et al.Fluconazole assists berberine to kill fluconazole-resistant Candida albicans[J].Antimicrob Agents Chemother,2013,57(12):6016-6027.
[21] Li DD,Zhao LX,Mylonakis E,et al.In vitro and in vivo activities of pterostilbene against Candida albicans biofilms[J].Antimicrob Agents Chemother,2014,58(4):2344-2355.
[22] Sudbery PE.Growth of Candida albicans hyphae[J].Nat Rev Micro-boil,2011,9(10):737-748.
[23] Zhao LX,Li DD,Hu DD,et al.Effect of tetrandrine against Candida albicans biofilms[J].Plos One,2013,8(11):e79671.